title: High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.
abstract: High intrapatient tacrolimus variability has been associated with worse clinical outcomes postrenal transplantation. Theoretically, tacrolimus levels consistently outside the target therapeutic window may result in allograft dysfunction as subtherapeutic tacrolimus levels predispose to episodes of acute rejection, whereas supratherapeutic levels may cause nephrotoxicity.
  
  
  
  We investigated the effect of tacrolimus variability in a "Symphony" style low-dose tacrolimus based regime, by collecting data from 432 patients over a 4-year period.Three hundred seventy-six patients were included, with a mean follow-up of 1495 days. Tacrolimus variability 6 to 12 months after renal transplantation was calculated, and outcomes were compared in low (n = 186) and high variability (n = 190) groups.
  
  
  
  High variability patients were found to be at increased risk of rejection during the first posttransplant year (P = 0.0054) and to have reduced rejection-free survival (hazard ratio, 1.953; 95% confidence interval, 1.234-3.093; P = 0.0054). High variability patients had significantly worse (P < 0.0001) glomerular filtration rates at 1, 2, 3, and 4 years posttransplant. High variability patients were at increased risk of allograft loss (hazard ratio, 4.928; 95% confidence interval, 2.050-11.85; P = 0.0004).
  
  
  
  This suggests that highly variable tacrolimus levels predict worse outcomes postrenal transplantation, although the causal nature of this relationship remains unclear. High tacrolimus variability may identify a subset of patients who warrant increased surveillance and patient education regarding dietary and medication compliance.
authors.affiliation: 1 West of Scotland Renal Transplant Unit, Queen Elizabeth University Hospital, Glasgow, Scotland. 2 School of Medicine, University of Glasgow, Glasgow, Scotland. 3 Royal Hospital for Children, Glasgow, Scotland.
authors.forename: Henry R
authors.initials: HR
authors.lastname: Whalen
authors.forename: Julie A
authors.initials: JA
authors.lastname: Glen
authors.forename: Victoria
authors.initials: V
authors.lastname: Harkins
authors.forename: Katherine K
authors.initials: KK
authors.lastname: Stevens
authors.forename: Alan G
authors.initials: AG
authors.lastname: Jardine
authors.forename: Colin C
authors.initials: CC
authors.lastname: Geddes
authors.forename: Marc J
authors.initials: MJ
authors.lastname: Clancy
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D065095:Calcineurin Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D018572:Disease-Free Survival; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D057286:Electronic Health Records; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006084:Graft Rejection / Q000175:diagnosis / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D053208:Kaplan-Meier Estimate; D007668:Kidney / Q000187:drug effects* / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D007674:Kidney Diseases / Q000139:chemically induced; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D012606:Scotland; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016559:Tacrolimus